NASHUA, N.H., April 10 /PRNewswire-FirstCall/ -- iCAD(R), Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions, today announced signing of a distribution agreement with Sectra, a major diagnostic imaging and PACS provider. iCAD will customize its SecondLook Digital solution for Sectra MicroDose Mammography. SecondLook Digital will broaden and strengthen Sectra's digital mammography and PACS offerings by providing computer-aided cancer detection capabilities.
"The combination of Sectra's and iCAD's products will deliver exceptional diagnostic sensitivity and minimum radiation exposure, enhancing patient care," said Jesper Soderqvist, Managing Director of Sectra's Mammography Product Division. "Having iCAD's detection software integrated into Sectra's mammography solution enables our customers to maximize the benefits of digital imaging."
"iCAD is proud to partner with Sectra, one of the world's leading diagnostic imaging system providers," said Ken Ferry, President and CEO of iCAD. "iCAD will optimize the performance of our powerful SecondLook detection algorithms for Sectra's unique photon-counting technology to help increase usage of CAD throughout Europe. Seamless integration of these two products will enable radiologists to provide better clinical results faster, improving diagnostic accuracy and clinical workflow."
Using sophisticated algorithms, iCAD detection software enables earlier cancer detection which allows less invasive and more effective treatment options, enhancing patient care. iCAD's algorithms have been shown to detect up to 72 percent of actionable missed cancers an average of 15 months earlier than mammography alone.
About Sectra's Medical OperationsSectra is one of the world's major diagnostic imaging system (PACS) providers. More than 900 hospitals worldwide use the system daily and more than 40 million radiology examinations are diagnosed in Sectra's system annually. In Scandinavia, Sectra is the market leader with more than 50% of all film-free installations. Outside Scandinavia, Sectra's system is installed at customers in North America and most major countries in Europe and the Far East.
About iCAD, Inc.iCAD, Inc. is an industry-leading provider of Computer- Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by almost one thousand women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit www.icadmed.com
For iCAD investor relations, contact Kevin McGrath of Cameron Associates at 212-245-4577 or via email at kevin@cameronassoc.com.
For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via e-mail at icad@schwartz-pr.com
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
iCAD, Inc.CONTACT: iCAD investor relations, Kevin McGrath of Cameron Associates,+1-212-245-4577, kevin@cameronassoc.com; or iCAD Public Relations, WendyRyan of Schwartz Communications, +1-781-684-0770, icad@schwartz-pr.com
Web site: http://www.icadmed.com//
